We believe that every breakthrough in medicine begins with a bold question: ‘What if?’ What if we could accelerate drug discovery? What if we could eliminate inefficiencies in clinical trials? What if we could empower scientists to create life-saving treatments faster? At Trial Genasys, our AI solutions are built with one purpose—to help biotech and pharmaceutical innovators transform possibilities into realities. We exist because patients deserve better, because time matters, and because the future of healthcare depends on technology that works for humanity.

Tofflon Science and Technology Group Co. Ltd. (Short for "Tofflon", Stock Code: SZ 300171) was founded in 1993. It is a comprehensive pharmaceutical equipment supplier to provide process support, core equipments, integrated system and pharma engineering for the pharma and biotech industry in the world. Since its foundation, Tofflon has supplied more than 8000 equipments and systems for 2000 pharmaceutical companies across over 40 countries and regions in the world which have been widely applied in the fields of liquid and lyo injectables, chemical API, bioengineering and pharma packaging, etc. Today Tofflon focuses on studying the science of drug and process equipment manufacture, practices drug process knowledge integration with pharma equipment knowledge. Taking "Synergy Global Advanced Technologies" strategy, Tofflon builds comprehensive development institute in Shanghai headquarters, is building design houses and technical centers in USA, Europe and India, establishes joint ventures and technology collaboration with the technical partners from USA, Europe and Japan. Furthermore Tofflon has built five modern pharmaceutical equipments manufacturing bases with global competitiveness. It has been approved with all the international regulatory certifications like German TUV ISO9001, ISO14001, OHSAS 18001, CE, UL, PED, ASME, etc. Thanks to 2000 Chinese and foreign employees professional works, it can provide competitive pharmaceutical equipment and system solutions valuable for today and future's competence improvement of the pharma and biotech companies. Future to commit to its mission "Expertise in Pharmaceutical Industry", Tofflon will continuously work with pharmaceutical industry to face and meet the challenges and demands in the industry through developing "innovative drug manufacturing science"and building "advanced drug manufacturing platform". In the following years, Tofflon will dedicate itself to grow from "China Tofflon to Global Tofflon".

Manufacturer of medical test instruments. The company designs, manufactures and distributes analytical test instruments for the biotech, pharmaceutical, government, and academic environments.

Consilx is an award winning technology platform provider for decentralized clinical trials. ConsilX is founded by senior executives with extensive experience in clinical drug development, service industries and academic research institutions. Our clients include Top-10 Pharma, Global CRO Consortium, mid-tier CROs, and Research organizations. The digital platforms provided Consilx are: a) Digital Consenting platform for site-based & remote consenting. We also have an eConsent-Lite. b) Patient Engagement solutions including visits tracking, medications compliance, adverse event alerts, etc. c) Direct Data Capture through eSource (for site-based & tele-visits), eDiaries, questionnaires, wearables, devices d) Telemedicine - Online video and audio communication between site and patients and related workflows e) LifeLedger™ - Decentralized trial platform managing the entire conduct of a clinical trial f) Blockchain-based Micro Platforms for data notarization, post-trial data access to patients for permissioned sharing, verified & automated data and documents exchange amongst clinical trial partners Visit us at www.consilx.com or write to us at info@consilx.com for more information.

Shandong Longzen Pharmaceutical Co., Ltd., a subsidiary and manufacturing site of Suzhou Medinoah Co., Ltd. was established in December 2020. It is located in ZouPing National Economic and Technological Development Zone of Shandong Province. Covering an area of 40 acres with a construction area of 95,000 square meters, the total investment has surpassed US$100 million. Upon the successful completion of the Phase 1 construction, Longzen presently commands an annual production capacity of 350 tons of alpha-Lipoic acid, 572 tons of other drug substances, 30 million bottles of injectables, and 2 billion tablets (capsules) of solid drug products. Shandong Longzen Pharmaceutical Co., Ltd. represents a modern pharmaceutical company that seamlessly integrates product research and development, manufacturing, sales and marketing. In Longzen, we offer an array of alpha-lipoic acids and R-(+)-lipoic acid in pharma and premium grades, catering to diverse required certifications and standards worldwide. These products find applications in various industries such as pharmaceutical, cosmetic, perfumery and more. In Longzen, we always ensure highest quality in all our products. We maintain a fully integrated process, including upstream manufacturing and sourcing of key raw materials. We also strictly adhere to Good Manufacturing Practices (GMP) throughout our entire process. As a result, our products boast an unmatched impurity profile in the market. In Longzen, we always believe excellent team shapes highest quality. Longzen's executive team members have more than 20 years of experience in drug research and development, with a particular emphasis on alpha-lipoic acid. In addition, Longzen maintains a dedicated R&D team capable of formulation R&D of lipoic acid to meet customer's requirements.

Since 2017, the BIH Digital Health Accelerator Program has been supporting employees from research and clinical departments at Charité - Universitätsmedizin Berlin, including the Berlin Institute of Health, in turning their innovative approaches into market- and application-ready digital health solutions. The broad spectrum of disciplines represented, unmet needs addressed, digital technologies used, and concrete areas of application ranging from prevention to prediction, diagnostics, therapy, and management to stakeholder empowerment and public health are evidence of the immense innovation potential. As a result, the supported project teams generate innovative digital health solutions that benefit patients and our society. The program is one of the key players in the digital health ecosystem in Berlin and beyond. Through its events series, including the Digital Health Forum, and its newsletter, the program connects the digital health community and all topics around it.

At ADS Processus PharmaTech LLP (APPL), we lead in enabling the transformative potential of advanced technologies for pharmaceutical and chemical industries. We offer a curated selection of cutting-edge technology to optimize your production processes. Our portfolio addresses industry-specific challenges, from enhancing research innovation to maximizing production efficiency and ensuring stringent quality control. Partnering with APPL means gaining a trusted advisor committed to your success in Continuous Manufacturing. We empower scientific and industrial progress through strategic technology implementation. Our vision is to be the foremost supporter of innovative technological solutions, fostering growth by connecting you with the best tools available. Our core values drive us: ethical business dealings, fostering mutually beneficial partnerships, and collaborative work with integrity. Specializations include Continuous Manufacturing, Process Analytical Technology, and Technology Skill Development. Industries served: Pharmaceutical, Fine Chemicals, Food & Nutraceuticals. Join us at ADS Processus PharmaTech LLP to unlock the true potential of Man, Machine, and Method for significant industrial advancements. #adspropharmatech #PharmaTech #Digitalization #Automation #ContinuousManufacturing #ProcessAnalyticalTechnology

Pion supports drug development programs with in vitro scientific instruments, contract research, and equipment maintenance. All designed to support more informed, more accurate, more timely decision making. Pion’s range of scientific instruments and services provide innovative solutions to the challenges of in vivo prediction, phys chem analysis, dissolution, and more. Clients may access Pion’s expertise either through the purchase of our instruments, or by contracting with our laboratories to run screens, assays and analysis on their behalf. Please contact sales@pion-inc.com or visit our website www.pion-inc.com

The Pharma University is your trusted resource for advancing expertise in the pharmaceutical industry. We specialize in delivering practical knowledge, industry insights, and innovative tools to empower professionals and organizations in validation, compliance, manufacturing engineering, and more. Our mission is to drive excellence in pharmaceutical education by bridging the gap between learning and application. Through engaging resources, expert-led courses, and a collaborative community, we help industry leaders and aspiring professionals stay ahead in a rapidly evolving field. Follow us to stay informed, grow your skills, and shape the future of pharmaceuticals. Together, we’re advancing knowledge and innovation.

QALB Holdings is an AI-powered technical consulting firm situated in London, UK. We are specialized in the Life Sciences sectors of Pharma, Biotech, and Medical Devices.

Vivtex strives to transform drug development using a new platform technology called gastrointestinal tract organ robotic interface system (GI-ORIS™) that enables robotic screening with fully intact and functional organs. GI-ORIS™ technology was developed in the Langer lab at MIT and can be used for various applications (e.g. oral delivery of biologics, drug toxicity mitigation, spatial and temporal drug delivery). Vivtex leverages these unique capabilities of the GI-ORIS™ to develop new oral therapeutics. Vivtex's mission is to serve patients by increasing the efficacy, safety and adherence of existing and novel therapies. The company is in preclinical stage and has multiple drug development programs including reformulations of existing drugs as well as new chemical entities. The company was co-founded by Professor Robert Langer (MIT), Dr. Giovanni Traverso (Harvard Medical School), Doug Eby (Cambridge Science), and Thomas von Erlach.

Minervate is a global GxP compliance and technological solutions company. We provide bespoke solutions helping your company deliver safe high-quality pharmaceutical products and maintaining patient safety, quality and integrity.

The Clinical Trials Technology Congress brings together those shaping and delivering this step change in the industry, allowing participants to share their visions for the future and practical steps they are taking now to improve the efficiency and effectiveness of Clinical Trials. The Congress will cover the business, regulatory and scientific drivers shaping clinical trials and how the industry is meeting these challenges particularly as it applies to the adoption of new disruptive technologies. Next Congress Date: 19th and 20th May 2026 at Kings Place, London

Pharmaceutical Industry

Expected to reach 3-5 billion by 2020 representing half of the world’s population, Africa’s population offers access to drug naïve patients in multiple disease areas as well as an underrepresented demographic in clinical trials. eMQT is uniquely placed as the bridge between the pharmaceutical, Biotechnology and Technology industries and Africa, utilizing research healthcare experts and technology enabled innovation to provide access to patients, high quality evidence based patient data and ultimately patient access to medicines.

Chemoproteomics and automation dual driver platform. Expand the target space and accelerate drug discovery

Revolutionizing Pharma & Clinical R&D with Proprietary AI Platforms At the forefront of innovation, we leverage our proprietary Artificial Intelligence Platforms and Models to deliver targeted, high-impact solutions that enhance efficiency across CMC, Clinical, and Pharmaceutical functions. AI for CMC (Chemistry, Manufacturing & Controls) We empower biopharma companies to streamline and scale their CMC operations through our AI-driven platform. From automated CMC documentation to intelligent regulatory submission support, our tools help teams optimize cost, time, quality, and compliance—ultimately accelerating clinical outcomes and patient access. Ready to transform your CMC processes? Let’s connect. AI for Clinical Trials & Development Our proprietary SMART (Schematic Arrangement by Routing Technologies) services simplify complex clinical trial processes. With intuitive AI models, even non-technical users—like physicians—can derive real-time insights from live clinical data, eliminating the dependency on data science teams. Smarter trials, faster results. AI for Pharmaceutical Support Functions From Drug Safety to Regulatory Affairs and Quality Management, our AI solutions reduce operational burden and enhance accuracy across critical support functions. We're enabling a new era in drug development—more agile, precise, and patient-focused. 🌐 AI is no longer the future—it's the now.

QbDVision is the leading Digital CMC Platform for pharmaceutical and biotech manufacturing. Created by industry veterans with decades of drug development experience, we understand the challenges our platform was built to solve. We are preparing our industry to deliver on its promise. We’re creating the modern digital tools our industry needs to realize the full potential of its science. A platform to help organizations swiftly and efficiently deliver the next generation of breakthrough therapies.

Pharmaceutical engineering and contracting

Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.

TPP Technology Company was established by engineers, doctors and leading experts in technology and science and engineering such as: Mechanical engineering, industrial electricity, production automation.... We I hope that experienced engineers and new graduates who are passionate about science and technology join hands to contribute to building a strong technology company on par with domestic and foreign technology companies.

The narrative centers on Biobox technology, encompassing proprietary intellectual property comprising advanced human progenitor cell/tissue-based systems and specifically tailored configurations. These in vitro/ex vivo human MicroPhysiological Systems present a multitude of permutations and combinations that can be utilized in conjunction with chemical toolboxes, Artificial Intelligence, and Machine Learning like complementary platform technologies. Collectively, these components lay the groundwork for developing real-world applications as distinctive offerings The biotechnology company is overseen by a proficient on-site team, guided by seasoned management. Shareholders embrace a hands-on approach that amalgamates entrepreneurial spirit and profound technical expertise with a dedicated focus on scientific pursuits. This approach is meticulously crafted to deliver a distinctive experience to stakeholders, including clients

BD is one of the largest global medical technology companies in the world and is advancing the world of health™ by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com. See community guidelines here: https://tinyurl.com/yunjmzkx.

Aprecia offers commercial-scale production systems designed to accelerate clinical development and optimize commercial success. Our industry-leading 3DP formulation and manufacturing platforms transform drug development and delivery, meeting the unprecedented demand for complex and patient-friendly dosage forms. Aprecia joined with MIT Technology to build groundbreaking 3DP pharmaceutical technology with a mission towards advancing personalized medicine. With the first-of-its-kind innovations, Aprecia enables NDAs, extends product lifestyles, and accelerates clinical development. · Powder-based 3DP techniques use the widest set of ready materials compared to other additive manufacturing techniques. · The Binder Jetting technique provides the most flexibility when creating pharmaceutical formulations. · Aprecia is the first and only company in the world to obtain regulatory approval for a 3DP pharmaceutical product and utilized the MIT invented Binder Jetting technique to realize that feat. This transformed the use of 3DP from rapid prototyping in a laboratory setting to at scale production in a cGMP environment. Aprecia is a sister company of PRASCO The Leader In Authorized Generics and Trusted Pharmaceutical Partner Aprecia is poised to revolutionize pharmaceutical manufacturing through precision medicine and distributed manufacturing.

We're enabling the next generation of data-driven, personalized, and engaging life sciences marketing through streamlined, AI-powered MLR review technology. Our mission is to optimize the release cycle, reduce cost, and eliminate compliance risk of releasing promotional materials in the pharmaceutical industry, while improving quality and consistency. We achieve this by applying deep industry knowledge in cutting-edge technology to automate the compliance requirements and best practices for our customers. We strive not only to uphold the highest standards of accuracy and compliance, but also to enable the generation of data-driven, personalized, and engaging content that results in positive patient outcomes. At the heart of our offerings is our AI-driven platform that learns from regulations, industry best practices, and our customers’ historical actions. Recommendations provided by our platform significantly reduce promotional material release time, and this level of efficiency has already earned us the trust of a Top 5 pharmaceutical company. At Revisto, we believe in transparency and understand that trust is earned through consistent performance and open communication. We are committed to delivering results for our customers and fostering relationships built on mutual respect and shared success. Join us as we continue to innovate and shape the future of pharmaceutical marketing.